MCID: GST023
MIFTS: 52

Gastric Ulcer

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastric Ulcer

MalaCards integrated aliases for Gastric Ulcer:

Name: Gastric Ulcer 12 54 15 17 70 32
Acute Gastric Ulcer Without Mention of Hemorrhage or Perforation, Without Mention of Obstruction 12
Chronic Gastric Ulcer Without Hemorrhage and Without Perforation but with Obstruction 12
Chronic Gastric Ulcer Without Mention of Hemorrhage or Perforation, with Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation, Without Mention of Obstruction 12
Acute Gastric Ulcer Without Hemorrhage, Without Perforation and Without Obstruction 12
Acute Gastric Ulcer with Hemorrhage and with Perforation but Without Obstruction 12
Acute Gastric Ulcer with Hemorrhage, with Perforation and with Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation, with Obstruction 12
Chronic Gastric Ulcer Without Hemorrhage and Without Perforation 12
Acute Gastric Ulcer Without Hemorrhage and Without Perforation 12
Acute Gastric Ulcer with Perforation, with Obstruction 12
Acute Gastric Ulcer with Hemorrhage, with Obstruction 12
Acute Gastric Ulcer with Haemorrhage and Perforation 12
Acute Gastric Ulcer with Perforation and Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation 12
Acute Gastric Ulcer with Perforation 12
Bleeding Acute Gastric Ulcer 12
Gastric Ulcers 15
Stomach Ulcer 44

Classifications:



External Ids:

Disease Ontology 12 DOID:10808
ICD9CM 34 531
MeSH 44 D013276
NCIt 50 C3388
SNOMED-CT 67 155681009
ICD10 32 K25
UMLS 70 C0038358

Summaries for Gastric Ulcer

MalaCards based summary : Gastric Ulcer, also known as acute gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and helicobacter pylori infection. An important gene associated with Gastric Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Rebamipide and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and endothelial, and related phenotypes are digestive/alimentary and hematopoietic system

Related Diseases for Gastric Ulcer

Diseases related to Gastric Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 869)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.6 S100A8 PTGS2 PTGS1 HRH2 GAST FGF2
2 helicobacter pylori infection 31.2 TNF IL1RN IL1B CYP2C19 CXCL8
3 hernia, hiatus 31.0 HRH2 GAST CYP2C19
4 microinvasive gastric cancer 30.7 TP53 S100A8 GAST
5 peptic ulcer perforation 30.6 S100A8 HRH2
6 peritonitis 30.5 TNF IL6 IL1B CXCL8
7 bile reflux 30.3 TFF1 S100A8 PTGS2 GAST
8 adenocarcinoma 30.3 TP53 PTGS2 MMP9 HGF EGF
9 gastric adenocarcinoma 30.2 TP53 S100A8 PTGS2 GAST
10 duodenitis 30.1 TNF S100A8 GAST
11 pleurisy 30.1 TNF IL1RN CXCL8
12 amebiasis 30.1 TNF IL1B CXCL8
13 crohn's colitis 30.1 TNF IL1B CXCL8
14 pustulosis of palm and sole 30.1 TNF IL1RN CXCL8
15 churg-strauss syndrome 30.1 TNF IL1B CXCL8
16 peptic ulcer disease 30.1 TP53 TNF SST S100A8 PTGS2 PTGS1
17 varicose veins 30.1 TNF MMP9 IL6 CXCL8
18 zollinger-ellison syndrome 30.0 SST HRH2 GAST EGF
19 status asthmaticus 30.0 MMP9 IL1RN CXCL8
20 lymphadenitis 30.0 TNF IL1B CXCL8
21 cardiogenic shock 30.0 TNF IL6
22 pancreatitis 29.9 TNF SST IL6 IL1B
23 graft-versus-host disease 29.9 TNF IL6 IL1B
24 obstructive jaundice 29.8 TNF IL6 HGF CXCL8
25 human cytomegalovirus infection 29.8 IL6 IL1B CXCL8
26 candidiasis 29.8 TNF IL6 IL1B CXCL8
27 gastroparesis 29.7 SST HRH2 GAST
28 cholecystitis 29.7 TP53 S100A8 EGF CALCA
29 stomatitis 29.7 TNF IL6 IL1B CXCL8
30 exanthem 29.7 TNF IL6 IL1B CXCL8
31 pericarditis 29.7 TNF IL6 IL1B CXCL8
32 toxic shock syndrome 29.7 TNF IL6 IL1RN IL1B CXCL8
33 actinomycosis 29.7 TNF IL6 IL1B
34 ulcerative colitis 29.7 TNF IL6 IL1RN IL1B CXCL8
35 diverticulitis 29.7 TNF MMP9 IL6 FGF2
36 active peptic ulcer disease 29.6 SST PTGS2 PTGS1 HRH2 CYP2C19
37 enterocolitis 29.6 TNF IL6 CXCL8
38 allergic disease 29.6 TNF IL6 IL1B CXCL8
39 typhoid fever 29.6 TNF IL6 IL1B
40 spondylitis 29.6 TNF IL6 IL1B
41 bronchitis 29.6 TNF MMP9 IL6 IL1B CXCL8
42 cholera 29.6 TNF IL6 IL1B EGF
43 aphthous stomatitis 29.6 TNF IL6 IL1RN IL1B CXCL8
44 arthropathy 29.5 TNF PTGS2 IL6 IL1B
45 dengue hemorrhagic fever 29.5 TNF IL6 CXCL8
46 liver disease 29.5 TNF IL6 IL1B HGF CXCL8
47 spondyloarthropathy 1 29.5 TNF IL6 IL1RN
48 cerebrovascular disease 29.5 TNF MMP9 IL6 CYP2C19
49 end stage renal disease 29.5 TNF IL6 IL1RN IL1B
50 severe acute respiratory syndrome 29.5 TNF IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Gastric Ulcer:



Diseases related to Gastric Ulcer

Symptoms & Phenotypes for Gastric Ulcer

MGI Mouse Phenotypes related to Gastric Ulcer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.11 EGF GAST HRH2 IL6 MMP9 PTGS1
2 hematopoietic system MP:0005397 10.1 FGF2 HGF IL1B IL1RN IL6 MMP9
3 immune system MP:0005387 10.03 EGF GAST IL1B IL1RN IL6 MMP9
4 integument MP:0010771 9.85 EGF IL1B IL1RN IL6 MMP9 PSCA
5 neoplasm MP:0002006 9.7 FGF2 GAST IL1B IL6 MMP9 PSCA
6 skeleton MP:0005390 9.4 FGF2 HGF IL1B IL1RN IL6 MMP9

Drugs & Therapeutics for Gastric Ulcer

Drugs for Gastric Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rebamipide Approved, Investigational Phase 4 90098-04-7
2
Clarithromycin Approved Phase 4 81103-11-9 84029
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
6
Misoprostol Approved Phase 4 59122-46-2 5282381
7
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
8
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
9
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
10
Famotidine Approved Phase 4 76824-35-6 3325
11 Benzimidazole Experimental, Investigational Phase 4 51-17-2
12
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
13 Protective Agents Phase 4
14 Antioxidants Phase 4
15
Bismuth Phase 4 7440-69-9 16682734 105143
16 Antiparasitic Agents Phase 4
17 Anti-Infective Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Anti-Infective Agents, Local Phase 4
21 Monoamine Oxidase Inhibitors Phase 4
22 Geranylgeranylacetone Phase 4
23 Neurotransmitter Agents Phase 4
24 Histamine H2 Antagonists Phase 4
25
Histamine Phosphate Phase 4 51-74-1 65513
26 Histamine Antagonists Phase 4
27
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
28
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
29
Racepinephrine Approved Phase 3 329-65-7 838
30
Sodium citrate Approved, Investigational Phase 3 68-04-2
31
Ranitidine Approved, Withdrawn Phase 3 66357-35-5, 66357-59-3, 82530-72-1 3001055
32
Potassium citrate Approved, Investigational, Vet_approved Phase 3 866-84-2
33
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
tannic acid Approved Phase 3 1401-55-4
36
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
37
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
38
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
39
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
40
Dexlansoprazole Approved, Investigational Phase 3 138530-94-6, 103577-45-3 9578005
41
Lansoprazole Approved, Investigational Phase 3 103577-45-3 3883
42
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
44
Gefarnate Investigational Phase 3 51-77-4
45 Cyclooxygenase 2 Inhibitors Phase 3
46 Fibrinolytic Agents Phase 3
47 Antipyretics Phase 3
48 Epinephryl borate Phase 3
49 Ranitidine bismuth citrate Phase 3
50 Citrate Phase 3

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
3 A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed NCT00125736 Phase 4 E0671;rabeprazole sodium;E0671 placebo
4 A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy Completed NCT00272467 Phase 4 Rebamipide;Omeprazole
5 A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy Completed NCT00233389 Phase 4 Rebamipide
6 An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours Completed NCT00428701 Phase 4 Esomeprazole Sodium
7 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Completed NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone;Esomeprazole;Bismuth
8 A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
9 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
10 Dilapan vs Misoprostol for Cervical Ripening [COMRED - Comparison of Misoprostol Ripening Efficacy With Dilapan] Completed NCT03670836 Phase 4 Misoprostol
11 Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
12 Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery Terminated NCT00839488 Phase 4 pantoprazole 40 mg iv;famotidine 20 mg iv
13 Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Withdrawn NCT03038009 Phase 4 Pantoprazole
14 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
15 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
16 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT01129011 Phase 3 PN400 (VIMOVO);Naproxen
17 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT00527787 Phase 3 PN400 (VIMOVO);Naproxen
18 A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin Completed NCT00175032 Phase 3 Lansoprazole and naproxen and aspirin;Celecoxib and aspirin
19 A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer Completed NCT02761512 Phase 3 CJ-12420 50 mg QD;CJ-12420 100 mg QD;Lansoprazole 30 mg QD
20 Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection Completed NCT03220334 Phase 3 Platelet rich plasma;Normal saline
21 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
22 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
23 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
24 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID). Completed NCT01452750 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
25 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
26 A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629512 Phase 3 Esomeprazole;Esomeprazole;Placebo
27 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
28 A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued Completed NCT00633672 Phase 3 Esomeprazole;Ranitidine;Esomeprazole
29 A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only Completed NCT00633412 Phase 3 Esomeprazole;Ranitidine;Esomeprazole
30 A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers Completed NCT00995410 Phase 3 PA32540
31 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00960869 Phase 3 PA32540;EC-Aspirin 325 mg
32 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00961350 Phase 3 PA32540;EC Aspirin 325
33 A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients Completed NCT01150162 Phase 3 Rebamipide and Omeprazole;Omeprazole
34 A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued Completed NCT00401752 Phase 3 Esomeprazole;Ranitidine
35 A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Gastric Ulcer. Completed NCT01452711 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
36 A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection Completed NCT03050307 Phase 3 TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
37 A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA) Completed NCT00441727 Phase 3 Esomeprazole 40 mg;Esomeprazole 20 mg;Placebo
38 A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00595517 Phase 3 Esomeprazole 20 mg
39 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
40 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
41 Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study Completed NCT02166008 Phase 2, Phase 3 Repamipide;Placebo
42 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
43 A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT00527904 Phase 3 PN400 (VIMOVO);PN 400 (VIMOVO)
44 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo
45 A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates Completed NCT01063920 Phase 2, Phase 3 LT-NS001;Naprosyn®
46 Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study) Completed NCT00153673 Phase 3 celecoxib;Dologesics
47 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Completed NCT00367211 Phase 3 PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Naproxen 500 mg tablets (PN 200 minus omeprazole)
48 Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
49 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
50 High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment Completed NCT00132171 Phase 3 Sequential therapy

Search NIH Clinical Center for Gastric Ulcer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
Atropine
Atropine Sulfate
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cat's Claw preparation
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
lansoprazole
magaldrate
Magnesium Hydroxide
Methylatropine nitrate
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Sucralfate

Cochrane evidence based reviews: stomach ulcer

Genetic Tests for Gastric Ulcer

Anatomical Context for Gastric Ulcer

MalaCards organs/tissues related to Gastric Ulcer:

40
Liver, Pancreas, Endothelial, Heart, Brain, Bone, Spleen

Publications for Gastric Ulcer

Articles related to Gastric Ulcer:

(show top 50) (show all 10811)
# Title Authors PMID Year
1
Expression of cyclooxygenase isoforms in ulcerated tissues of the nonglandular portion of the stomach in horses. 61 54
20433387 2010
2
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 61 54
19930551 2009
3
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 54 61
18612816 2009
4
The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. 61 54
19120912 2008
5
The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. 61 54
19260336 2008
6
Gene therapy for gastric diseases. 61 54
18537593 2008
7
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. 61 54
17934843 2008
8
Effects of Helicobacter pylori Infection on gastric mucin expression. 54 61
18097286 2008
9
[Expression of hepatocyte growth factor and its receptor in gastric cancer]. 54 61
18024311 2007
10
[The choice of selective COX-2 inhibitors]. 54 61
17926530 2007
11
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer]. 54 61
17717918 2007
12
Restriction fragment length polymorphism of virulence genes cagA, vacA and ureAB of Helicobacter pylori strains isolated from Iranian patients with gastric ulcer and nonulcer disease. 61 54
17457472 2007
13
Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. 54 61
17539287 2007
14
Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. 54 61
17380018 2007
15
Molecular forms of trefoil factor 1 in normal gastric mucosa and its expression in normal and abnormal gastric tissues. 61 54
17143957 2006
16
Influence of COX-2 and local cytokine expressions in gastric ulcer mucosa by H. pylori and NSAID. 61 54
17086892 2006
17
Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts. 61 54
16357062 2006
18
Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer. 61 54
16718800 2006
19
Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug. 54 61
16375889 2006
20
[Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases]. 54 61
16353543 2005
21
Recent advances in gastric ulcer therapeutics. 54 61
16188503 2005
22
Roles of platelets and proteinase-activated receptors in gastric ulcer healing. 54 61
16184414 2005
23
Cellular and molecular mechanisms of gastrointestinal ulcer healing. 61 54
16184417 2005
24
The role of cyclooxygenase in gastric mucosal protection. 54 61
16184416 2005
25
Protective role of heat shock protein 27 in gastric mucosal injury. 54 61
16041694 2005
26
[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. 61 54
16174594 2005
27
Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. 54 61
15849833 2005
28
Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa. 61 54
15720413 2005
29
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. 61 54
15531909 2005
30
Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. 61 54
16325508 2005
31
Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs. 54 61
15213313 2004
32
Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. 54 61
15246970 2004
33
Serum response factor promotes re-epithelialization and muscular structure restoration during gastric ulcer healing. 54 61
15188176 2004
34
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers. 61 54
15086596 2004
35
[The expression of trefoil factor 1 and trefoil factor 2 in gastric cancer and precancer]. 61 54
15059374 2004
36
Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide. 61 54
12925150 2003
37
Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation? 54 61
12679615 2003
38
Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. 54 61
12678329 2003
39
Mucosal repair and COX-2 inhibition. 61 54
14529401 2003
40
Relationship between gastric disease and deletion of cag pathogenicity island genes of Helicobacter pylori in gastric juice. 54 61
12645789 2003
41
COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. 61 54
14529402 2003
42
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. 61 54
12232050 2002
43
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. 61 54
12217640 2002
44
[Seroprevalence of antibodies against Helicobacter pylori CagA antigen in patients with gastric ulcer in the North region of Brazil]. 54 61
12170324 2002
45
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. 54 61
11943947 2002
46
Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. 61 54
11677194 2001
47
Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. 61 54
11519793 2001
48
[Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and usefulness in the control of the eradication]. 54 61
11247290 2001
49
Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. 61 54
11252403 2001
50
Consensus and variable region PCR analysis of Helicobacter pylori 3' region of cagA gene in isolates from individuals with or without peptic ulcer. 54 61
11158115 2001

Variations for Gastric Ulcer

Expression for Gastric Ulcer

Search GEO for disease gene expression data for Gastric Ulcer.

Pathways for Gastric Ulcer

Pathways related to Gastric Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TP53 TNF S100A8 PTGS2 MMP9 IL6
2
Show member pathways
13.86 TP53 TNF PTGS2 IL6 IL1B HGF
3
Show member pathways
13.72 TP53 TNF PTGS2 PTGS1 IL6 IL1RN
4
Show member pathways
13.58 TP53 TNF IL6 IL1B HGF FGF2
5
Show member pathways
13.45 TP53 TNF IL6 IL1B HGF FGF2
6
Show member pathways
13.34 TNF IL6 IL1B HGF FGF2 EGF
7
Show member pathways
13.31 TP53 TNF PTGS2 MMP9 IL6 IL1RN
8
Show member pathways
13.24 TP53 TNF MMP9 IL6 IL1B EGF
9
Show member pathways
13.01 TP53 TNF PTGS2 IL6 HGF FGF2
10
Show member pathways
12.95 TP53 TNF PTGS2 IL6 IL1B FGF2
11 12.85 TP53 PTGS2 MMP9 IL6 HGF FGF2
12 12.79 TP53 TNF IL1B HGF FGF2 EGF
13
Show member pathways
12.75 TNF PTGS2 IL6 IL1RN IL1B CXCL8
14
Show member pathways
12.73 TNF IL6 IL1B HGF FGF2 EGF
15
Show member pathways
12.72 TP53 MMP9 HGF FGF2 EGF
16
Show member pathways
12.66 TP53 IL6 HGF FGF2 EGF
17
Show member pathways
12.63 TP53 TNF IL6 IL1B FGF2
18 12.61 TNF PTGS2 PTGS1 IL1RN IL1B
19 12.44 TP53 TNF IL1B CXCL8
20 12.42 HRH2 HGF FGF2 EGF
21
Show member pathways
12.36 TFF1 PTGS2 HRH2 EGF
22
Show member pathways
12.36 TP53 TNF PTGS2 PTGS1 IL6 IL1B
23 12.33 TP53 TNF MMP9 HGF FGF2
24
Show member pathways
12.32 TP53 TNF PTGS2 IL6 IL1B FGF2
25 12.31 TP53 MMP9 IL6 CXCL8
26
Show member pathways
12.29 TP53 TNF IL6 IL1B HGF FGF2
27 12.28 TNF IL6 IL1B CXCL8
28
Show member pathways
12.28 TNF S100A8 PTGS2 MMP9 IL6 IL1B
29
Show member pathways
12.26 TNF PTGS2 IL6 IL1B
30
Show member pathways
12.23 TNF IL6 IL1B CXCL8
31 12.2 TP53 TNF PTGS2 MMP9 IL6 EGF
32 12.18 TNF SST IL6 IL1RN IL1B CXCL8
33 12.14 TP53 TNF MMP9 IL1B
34 12.13 TNF IL6 IL1B CXCL8
35 12.11 IL6 HGF FGF2 EGF
36 12 TNF PTGS2 MMP9 IL6 IL1B
37 11.99 TP53 IL6 IL1B CXCL8
38 11.98 TNF PTGS2 IL1B CXCL8
39 11.97 TNF IL6 IL1B CXCL8
40 11.96 TNF IL6 IL1B CXCL8
41 11.92 TNF IL6 IL1B CXCL8
42 11.89 PTGS2 MMP9 HGF FGF2
43 11.88 TP53 TNF PTGS2 MMP9 IL6 IL1B
44 11.8 TNF IL6 IL1B CXCL8
45
Show member pathways
11.79 TNF IL6 IL1B
46
Show member pathways
11.79 TNF PTGS2 CXCL8
47 11.78 TNF IL6 IL1B
48 11.78 TP53 MMP9 EGF CXCL8
49 11.72 MMP9 IL6 CXCL8
50 11.67 TP53 TNF PTGS2 MMP9 IL6 IL1B

GO Terms for Gastric Ulcer

Cellular components related to Gastric Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF TFF1 SST S100A8 PSCA MMP9
2 extracellular space GO:0005615 9.47 TNF TFF1 SST S100A8 MMP9 IL6

Biological processes related to Gastric Ulcer according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 TFF1 IL6 IL1RN IL1B HRH2 GAST
2 positive regulation of transcription, DNA-templated GO:0045893 10.14 TP53 TNF IL6 IL1B FGF2 EGF
3 immune response GO:0006955 10.06 TNF IL6 IL1RN IL1B HRH2 CXCL8
4 positive regulation of apoptotic process GO:0043065 10.04 TP53 TNF PTGS2 MMP9 IL6
5 MAPK cascade GO:0000165 9.99 TNF IL1B HGF FGF2 EGF
6 regulation of cell proliferation GO:0042127 9.98 TP53 TNF PTGS2 PTGS1
7 positive regulation of gene expression GO:0010628 9.98 TP53 TNF IL6 IL1B FGF2 EGF
8 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF HGF FGF2 EGF
9 cellular response to lipopolysaccharide GO:0071222 9.94 TNF IL6 IL1B CXCL8
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF S100A8 IL6 IL1B
11 positive regulation of protein phosphorylation GO:0001934 9.93 TNF MMP9 IL1B HGF FGF2
12 positive regulation of angiogenesis GO:0045766 9.92 IL1B HGF FGF2 CXCL8
13 negative regulation of cell proliferation GO:0008285 9.91 TP53 TFF1 SST PTGS2 IL6 IL1B
14 regulation of insulin secretion GO:0050796 9.87 TNF IL6 IL1B
15 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.86 TNF PTGS2 HGF
16 regulation of blood pressure GO:0008217 9.86 PTGS2 PTGS1 CALCA
17 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 TP53 IL6 HGF EGF
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF PTGS2 IL6
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 TNF HGF FGF2 EGF
20 positive regulation of MAP kinase activity GO:0043406 9.84 TNF FGF2 EGF
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.83 TNF MMP9 FGF2
22 response to glucocorticoid GO:0051384 9.81 TNF PTGS2 IL6 IL1RN
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF PTGS2 IL1B
24 positive regulation of interleukin-8 production GO:0032757 9.8 TNF IL6 IL1B CALCA
25 activation of MAPK activity GO:0000187 9.8 TNF IL1B HGF FGF2 EGF
26 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.78 TP53 TNF FGF2
27 positive regulation of vascular endothelial growth factor production GO:0010575 9.75 PTGS2 IL6 IL1B
28 negative regulation of neurogenesis GO:0050768 9.74 TNF IL6 IL1B
29 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
30 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
31 response to salt stress GO:0009651 9.69 TP53 TNF
32 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
33 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.67 IL6 IL1RN
34 positive regulation of prostaglandin biosynthetic process GO:0031394 9.67 PTGS2 IL1B
35 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6 IL1B
36 negative regulation of smooth muscle contraction GO:0045986 9.64 PTGS2 CALCA
37 regulation of neuroinflammatory response GO:0150077 9.63 PTGS2 MMP9 IL6
38 positive regulation of epithelial tube formation GO:1905278 9.62 FGF2 EGF
39 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
40 inflammatory response GO:0006954 9.61 TNF S100A8 PTGS2 PTGS1 IL6 IL1RN
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 TNF IL1B
42 embryo implantation GO:0007566 9.56 PTGS2 MMP9 IL1B CALCA
43 vascular endothelial growth factor production GO:0010573 9.5 TNF IL6 IL1B
44 positive regulation of fever generation GO:0031622 9.33 TNF PTGS2 IL1B
45 cytokine-mediated signaling pathway GO:0019221 9.32 TP53 TNF PTGS2 MMP9 IL6 IL1RN

Molecular functions related to Gastric Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 TFF1 IL6 HGF FGF2 EGF
2 prostaglandin-endoperoxide synthase activity GO:0004666 9.16 PTGS2 PTGS1
3 cytokine activity GO:0005125 9.1 TNF IL6 IL1RN IL1B FGF2 CXCL8

Sources for Gastric Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....